Fiche publication
Date publication
août 2015
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe
,
Pr NAMER Izzie-Jacques
Tous les auteurs :
Imperiale A, Bahougne T, Goichot B, Bachellier P, Taïeb D, Namer IJ
Lien Pubmed
Résumé
(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with insulinoma.
Mots clés
Adult, Carbidopa, Dihydroxyphenylalanine, analogs & derivatives, Female, Humans, Hyperinsulinism, complications, Hypoglycemia, complications, Insulinoma, complications, Male, Middle Aged, Multimodal Imaging, Pancreatic Neoplasms, complications, Positron-Emission Tomography, Premedication, Radiopharmaceuticals, Tomography, X-Ray Computed
Référence
Clin Nucl Med. 2015 Aug;40(8):682-4
